Quarterly Report of BioNTech SE for the Three And Six Months Ended June 30, 2023 Unaudited Interim Condensed Consolidated Financial Statements Interim Condensed Consolidated Statements of Changes in Stockholders' Equity 4 2 Basis of Preparation, Significant Accounting Policies and further Accounting Topics 6 6 Intangible Assets 12 10 Share-Based Payments 15 Operating and Financial Review and Prospects The accompanying notes form an integral part of these interim consolidated financial statements. 1 2 3 4 Th ...

analogs to trastuzumab, deruxtecan and trastuzumab emtansin, respectively. In red monkey and human plasma, DB-1303 demonstrated high drug to antibody ratio and outstanding plasma stability. Two points to that. So first is actually the volumes, while we're not disclosing volumes in the first quarter, we were shipping to quite a broad range of countries in the first quarter, over 70 countries we mentioned. There's still some carryover there to pandemic contracts. And so, as I mentioned in the prepared remarks ...

The increase of intangible assets by €158.9 million during the three months ended March 31, 2023 is mainly due to licenses acquired that meet the definition of identifiable assets in the amount of €158.0 million in connection with the License and Collaboration Agreements entered into between us and Duality Biologics (Suzhou) Co. Ltd., Shanghai, China, in March 2023. Set out below is an overview of financial assets, other than cash and cash equivalents, held as of March 31, 2023 and December Derivatives not ...

BioNTech SE (NASDAQ:BNTX) Q4 2022 Results Conference Call March 27, 2023 8:00 AM ET Company Participants Michael Horowicz - IR and Strategy Ugur Sahin - CEO and Co-Founder Özlem Türeci - Chief Medical Officer and Co-Founder Jens Holstein - CFO Ryan Richardson - Chief Strategy Officer Conference Call Participants Tazeen Ahmad - Bank of America Daina Graybosch - SVB Securities Matthew Harrison - Morgan Stanley Yaron Werber - Cowen Jessica Fye - JP Morgan Michael Horowicz Good morning and afternoon. Thank you ...

Title of each classTrading Symbol(s)Name of each exchange on which registered Ordinary shares, no par value, with a notional amount attributable to each ordinary share of €1* — The Nasdaq Stock Market LLC* FORM 20-F Securities registered or to be registered, pursuant to Section 12(b) of the Act Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Page GENERAL INFORMATION 3 CAUTIONARY STATEMENT RE ...

Financial Performance - Total revenues for the year ended December 31, 2022, were €17,310.6 million, a decrease of 8.8% compared to €18,976.7 million for the prior year[8]. - Net profit for the year ended December 31, 2022, was €9,434.4 million, down 8.3% from €10,292.5 million in the previous year[16]. - Total revenues for Q4 2022 were €4,278.3 million, a decrease of 22.7% compared to €5,532.5 million in Q4 2021[60]. - Commercial revenues decreased to €4,271.3 million in Q4 2022 from €5,525.9 million in Q4 2021, representing a decline of 22.7%[60]. - Profit for the period in Q4 2022 was €2,278.7 million, down from €3,166.2 million in Q4 2021, a decrease of 28.1%[60]. - Basic profit for the period per share was €9.38 in Q4 2022, compared to €12.96 in Q4 2021, a decline of 27.5%[60]. - Full year 2022 revenues reached €17.3 billion, with a net profit of €9.4 billion and fully diluted earnings per share of €37.77[65]. Research and Development - BioNTech plans to continue investing heavily in R&D and is open to mergers and acquisitions to drive future growth[4]. - Research and development expenses increased to €509.8 million in Q4 2022, up from €271.5 million in Q4 2021, reflecting an increase of 87.7%[60]. - The company expanded its oncology pipeline to 20 programs with 24 ongoing clinical trials, including five randomized Phase 2 trials[65]. - Estimated R&D expenses for 2023 are projected to be between €2,400 million and €2,600 million[70]. - BioNTech initiated multiple clinical trials in 2022, including programs for non-small cell lung cancer and a herpes simplex virus vaccine candidate[27][24]. - BioNTech plans to start a Phase 3 trial of ONC-392 in NSCLC patients in 2023, following an exclusive licensing agreement with OncoC4, Inc.[39]. - The company announced a licensing agreement with OncoC4 to enhance its oncology portfolio, with a Phase 3 trial planned for 2023[65]. Vaccine Development and Sales - BioNTech expects COVID-19 vaccine revenues for the 2023 financial year to be approximately €5 billion[11]. - BioNTech and Pfizer invoiced approximately 2 billion doses of the COMIRNATY vaccine globally in 2022, including around 550 million doses of the adapted bivalent vaccine[19]. - The company launched the world's first Omicron BA.4/BA.5 adapted bivalent COVID-19 vaccine in 2022 and progressed nine new programs into clinical trials[1]. - Approximately 2 billion doses of COMIRNATY were invoiced in 2022, including around 550 million doses of Omicron-adapted bivalent COVID-19 vaccines[65]. Financial Position - Total assets increased to €23,279.1 million as of December 31, 2022, from €15,830.8 million as of December 31, 2021, an increase of 47.0%[50]. - Total current assets rose to €21,922.0 million in 2022 from €15,072.3 million in 2021, an increase of 45.0%[50]. - Total equity increased to €20,055.6 million in 2022 from €11,893.7 million in 2021, representing an increase of 68.5%[50]. - Cash and cash equivalents significantly increased to €13,875.1 million in 2022 from €1,692.7 million in 2021, a rise of 718.5%[50]. - Total liabilities decreased to €32,223.5 million in 2022 from €39,371.1 million in 2021, a reduction of 18.2%[50]. - Net cash flows from operating activities for the year were €13,577.4 million, compared to €889.7 million in the previous year[63]. Expenses - The cost of sales for the year ended December 31, 2022, was €2,995.0 million, a slight increase of 2.9% from €2,911.5 million in the prior year[2]. - General and administrative expenses for the year ended December 31, 2022, were €484.7 million, an increase of 69.5% from €285.8 million in the prior year[9]. - Research and development expenses for Q4 2022 were €509.8 million, compared to €271.5 million in the same period last year, reflecting an increase of 87.7%[67]. Strategic Initiatives - BioNTech's acquisition of InstaDeep Ltd. is expected to add approximately 240 skilled professionals to its workforce, enhancing capabilities in AI and machine learning[39]. - BioNTech's share repurchase program authorized up to $0.5 billion, with a total of approximately $1.3 billion spent to repurchase 9,166,684 ADSs at an average price of $142.04[38]. - BioNTech's ESG report for 2022 was published on March 27, 2023, detailing the company's sustainability efforts[40]. - The first six ISO-sized shipping containers for the BioNTainer were completed and shipped to Kigali in March 2023[39]. - BioNTech completed the construction of its first proprietary plasmid DNA manufacturing facility in Marburg in February 2023[39].

BioNTech SE (NASDAQ:BNTX) JP Morgan Annual Healthcare Conference January 10, 2023 12:45 PM ET Company Participants Ugur Sahin - Chief Executive Officer & Co-Founder Ryan Richardson - Chief Strategy Officer Conference Call Participants Jessica Fye - JPMorgan Jessica Fye Great. Good morning, everyone. My name is Jess Fye. I'm the large cap biotech analyst at JPMorgan, and we're delighted to be continuing the conference today with BioNTech. [Operator Instructions] So with that, let me turn it over to BioNTech ...

BioNTech SE (NASDAQ:BNTX) Q3 2022 Earnings Conference Call November 7, 2022 8:00 AM ET Company Participants Sylke Maas - Vice President, Investor Relations & Strategy Ugur Sahin - Chief Executive Officer & Co-Founder Ozlem Tureci - Chief Medical Officer & Co-Founder Jens Holstein - Chief Financial Officer Ryan Richardson - Chief Strategy Officer Conference Call Participants Tazeen Ahmad - Bank of America Chris Shibutani - Goldman Sachs Jessica Fye - JPMorgan Daina Graybosch - SVB Leerink Ellie Merle - UBS S ...

Exhibit 99.1 BIONTECH BioNTech SE Quarterly Report of BioNTech SE for the Three And Nine Months Ended September 30, 2022 Exhibit 99.1 Unaudited Interim Condensed Consolidated Financial Statements Interim Condensed Consolidated Statements of Profit or Loss 3 Interim Condensed Consolidated Statements of Comprehensive Income 4 Interim Condensed Consolidated Statements of Financial Position 5 Interim Condensed Consolidated Statements of Changes in Stockholders' Equity 6 Interim Condensed Consolidated Statements ...

BioNTech SE (NASDAQ:BNTX) Q2 2022 Earnings Conference Call August 8, 2022 8:00 AM ET Company Participants Sylke Maas - Vice President, Investor Relations and Strategy Ugur Sahin - Chief Executive Officer and Co-Founder Ozlem Tureci - Chief Medical Officer and Co-Founder Jens Holstein - Chief Financial Officer Ryan Richardson - Chief Strategy Officer Conference Call Participants Matthew Harrison - Morgan Stanley Tazeen Ahmad - Bank of America Daina Graybosch - SVB Securities Zhiqiang Shu - Berenberg Operator ...